VivoSeq
Other

Triple Negative

0

Pipeline Programs↗

2

Active Trials↗

0

Companies Involved↗

Triple Negative is an early-stage landscape with 0 programs across 0 companies.

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

7

clinical trials

Completed4 · 57%
Recruiting1 · 14%
Active, not recruiting1 · 14%
Unknown status1 · 14%

Clinical Trials

Trial Activity

7 trials

IvoLoC Trial: A Phase II Trial Evaluating the Efficacy of Ivonescimab in Metastatic Endocrine Refractory HR-positive HER2-negative or Triple Negative Invasive Lobular Carcinoma
Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT07229417·29 enrolled
CIPHER Study: Pilot Study to Study the Role of ctDNA in Triple Negative and HER2 Positive Early Stage
Active, not recruiting·RRutgers, The State University of New Jersey·Phase 1·NCT05333874·34 enrolled
Cabozantinib for Metastatic Triple Negative BrCa
Completed·—·Phase 2·NCT01738438·35 enrolled
Window of Opportunity Trial, PARP Inhibitor Rucaparib Affect on PD-L1 Expression in Triple Negative Breast Tumors
Completed·UUniversity of Arizona·Phase 1·NCT03911453·20 enrolled
Ruxolitinib W/ Preop Chemo For Triple Negative Inflammatory Brca
Completed·—·Phase 1/2·NCT02041429·20 enrolled
Leflunomide in Previously Treated Metastatic Triple Negative Cancers
Completed·—·Phase 1/2·NCT03709446·17 enrolled
Evaluating the Efficacy of Neratinib on Live Cell HER2 Signaling Transduction Analysis Positive Triple Negative Breast
Unknown status·WWest Cancer Center·Phase 2·NCT03812393·27 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)